Skip to content

Study · Animal study (in vivo) · mouse · 2016

20 results

Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice.

Lu HI, Huang TH, Sung PH, Chen YL, Chua S, Chai HY, Chung SY, Liu CF, Sun CK, Chang HW, Zhen YY, Lee FY, Yip HK

Acta pharmacologica Sinica11 Apr 2016Cited by 39 (Europe PMC)

PMID27063219 (opens in a new tab)PMCIDPMC4857546 (opens in a new tab)DOI10.1038/aps.2015.162 (opens in a new tab)PepBankPUB-27063219
Source linkPubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with TAC-induced pulmonary arterial hypertension, SS‑31 suppressed the elevation of right ventricular systolic blood pressure.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced the rise in right ventricular blood pressure compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseRight ventricular systolic blood pressure
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    1 context sentence
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary oxidative stress proteins (NOX-1, NOX-2, oxidized proteins).

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung oxidative stress proteins compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary oxidative stress proteins
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Oxidative stress · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    oxidative stress proteins (NOX-1/NOX-2/oxidized proteins)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary cytosolic cytochrome c.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung cytochrome c, a cell-stress marker, compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary cytosolic cytochrome c
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Cell viability and death · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    cytosolic cytochrome c,
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary inflammation biomarkers (MMP-9, TNF-α, iNOS).

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung inflammation markers compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary inflammation biomarkers (MMP-9, TNF-α, iNOS)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    biomarkers related to inflammation (MMP-9/TNF-α/iNOS)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the pulmonary calcium overload index (TRPC1, 2, 4, 6).

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung markers of calcium overload compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary calcium overload index (TRPC1, 2, 4, 6)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    calcium overload index (TRPC1, 2, 4, 6)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary apoptosis markers (mitochondrial BAX, cleaved caspase 3, PARP).

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung cell-death markers compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary apoptosis markers
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Cell viability and death · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    apoptosis (mitochondrial BAX, cleaved caspase 3/PARP)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary fibrosis markers (Smad3, TGF-β).

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered lung scarring markers compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary fibrosis markers (Smad3, TGF-β)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    fibrosis (Smad3/TGF-β)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in pulmonary HIF-1α.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered a lung low-oxygen marker, HIF-1α, compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary hypoxia marker HIF-1α
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    hypoxic (HIF-1α)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the pulmonary DNA damage marker γ-H2AX.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered a lung DNA damage marker compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreasePulmonary DNA damage marker γ-H2AX
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    DNA damage (γ-H2AX)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 changed pulmonary endothelial function markers (eNOS, ET-1R) in the same pattern as the other markers, a suppression of the TAC-induced change.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 suppressed TAC-induced changes in lung blood-vessel lining markers compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedPulmonary endothelial function markers (eNOS, ET-1R)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    endothelial function (eNOS/ET-1R)
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In TAC mice, SS‑31 suppressed the TAC-induced rise in lung injury score.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 lowered a lung damage score compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseLung injury score
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    as well as in lung injury score,
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the number of muscularized vessels in lungs.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced the number of thickened lung vessels compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseNumber of muscularized vessels in lungs
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    number of muscularized vessels in lungs
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the number of TRPC1(+) cells in the pulmonary artery.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced TRPC1-positive cells in the lung artery compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseTRPC1-positive cells in pulmonary artery
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    number of TRPC1(+) and HIF-1α(+) cells in pulmonary artery
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the number of HIF-1α(+) cells in the pulmonary artery.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced HIF-1α-positive cells in the lung artery compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseHIF-1α-positive cells in pulmonary artery
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    number of TRPC1(+) and HIF-1α(+) cells in pulmonary artery
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the number of γ-H2AX(+) cells in lung parenchyma.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced DNA-damaged cells in lung tissue compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Decreaseγ-H2AX-positive cells in lung parenchyma
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    number of γ-H2AX(+) and Ki-67(+) cells in lung parenchyma
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 suppressed the TAC-induced rise in the number of Ki-67(+) cells in lung parenchyma.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 reduced dividing cells in lung tissue compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKi-67-positive cells in lung parenchyma
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    number of γ-H2AX(+) and Ki-67(+) cells in lung parenchyma
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  17. 17AnimalAnimal study (in vivo)Mechanism

    In TAC mice, SS‑31 produced an opposite pattern in pulmonary anti-fibrotic markers (Smad1/5, BMP-2): they were higher than in untreated TAC mice.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 raised lung anti-scarring markers compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePulmonary anti-fibrotic markers (Smad1/5, BMP-2)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    An opposite pattern of changes was observed in pulmonary anti-fibrotic markers (Smad1/5, BMP-2), number of small vessels, and number of alveolar sacs.
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In TAC mice, SS‑31 produced an opposite pattern in the number of small vessels: it was higher than in untreated TAC mice.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 increased the number of small lung vessels compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseNumber of small vessels in lungs
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    An opposite pattern of changes was observed in pulmonary anti-fibrotic markers (Smad1/5, BMP-2), number of small vessels, and number of alveolar sacs.
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In TAC mice, SS‑31 produced an opposite pattern in the number of alveolar sacs: it was higher than in untreated TAC mice.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 increased the number of lung air sacs compared with untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseNumber of alveolar sacs
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    An opposite pattern of changes was observed in pulmonary anti-fibrotic markers (Smad1/5, BMP-2), number of small vessels, and number of alveolar sacs.
    2 context sentences
    Summary · context
    TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice.
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.
  20. 20AnimalAnimal study (in vivo)Mechanism

    In mice, pulmonary antioxidant proteins (HO-1, NQO-1, GR, GPx) increased progressively from sham to TAC to TAC+SS‑31 mice.

    In plain wordsIn mice with pulmonary arterial hypertension, SS‑31 raised lung antioxidant proteins further than in untreated mice.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreasePulmonary antioxidant proteins (HO-1, NQO-1, GR, GPx)
    Study

    mousen: not reported in source

    Transverse aortic constriction-induced pulmonary arterial hypertension
    Comparator
    TAC mice without SS-31
    Outcome group
    Oxidative stress · Respiratory
    Studied dose
    2 mg/d · intraperitoneal · 60 daysAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, the levels of antioxidant proteins (HO-1/NQO-1/GR/GPx) in lung parenchyma were progressively and significantly increased from sham-operated mice, TAC mice to TAC+SS-31 mice.
    1 context sentence
    Summary · context
    Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.